Literature DB >> 10865931

Choosing drug therapy for patients with hyperlipidemia.

R S Safeer1, C L Lacivita.   

Abstract

Almost 13 million American adults require drug therapy to meet the low-density lipoprotein goals set by the National Cholesterol Education Program. Attempts to achieve these goals through diet and exercise are often unsuccessful. Major studies in recent years have demonstrated that statins decrease low-density lipoprotein levels, coronary events and overall mortality. Statins are the most commonly prescribed lipid-lowering agents because they are effective, well tolerated and easy to administer. Niacin has beneficial effects on all of the main lipid components, and new extended-release tablets have fewer adverse effects. Fibrates remain the most effective agents in lowering triglyceride levels and should be limited to this use. Bile acid sequestrants are seldom prescribed because of their adverse gastrointestinal effects and cumbersome administration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10865931

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  10 in total

Review 1.  Flaxseed and Its Components in Treatment of Hyperlipidemia and Cardiovascular Disease.

Authors:  Kailash Prasad; Amal S Khan; Muhammad Shoker
Journal:  Int J Angiol       Date:  2020-04-14

2.  [Therapeutic drug option for dyslipaemia].

Authors:  Antonio Maiques Galan; Carlos Brotons Cuixart
Journal:  Aten Primaria       Date:  2009-06-04       Impact factor: 1.137

Review 3.  Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.

Authors:  H S Malhotra; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  A method to account for covariate-specific treatment effects when estimating biomarker associations in the presence of endogenous medication use.

Authors:  Andrew J Spieker; Joseph Ac Delaney; Robyn L McClelland
Journal:  Stat Methods Med Res       Date:  2016-12-22       Impact factor: 3.021

Review 5.  Therapy to reduce risk of coronary heart disease.

Authors:  Daniel J Rader
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

6.  Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics.

Authors:  Chen-Chang Yang; Susan S Jick; Marcia A Testa
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 7.  Are cardiovascular disease and osteoporosis directly linked?

Authors:  Crystal Whitney; Darren E R Warburton; Jiri Frohlich; Sammy Y Chan; Heather McKay; Karim Khan
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

8.  Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation.

Authors:  Chen-Chang Yang; Susan S Jick; Marcia A Testa
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

Review 9.  The Effects and Potential Mechanism of Oil Palm Phenolics in Cardiovascular Health: A Review on Current Evidence.

Authors:  Nurul 'Izzah Ibrahim; Syed Fairus; Isa Naina Mohamed
Journal:  Nutrients       Date:  2020-07-10       Impact factor: 5.717

Review 10.  Interdependence of Anti-Inflammatory and Antioxidant Properties of Squalene-Implication for Cardiovascular Health.

Authors:  Nurul 'Izzah Ibrahim; Isa Naina Mohamed
Journal:  Life (Basel)       Date:  2021-01-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.